The investigation of killer-cell immunoglobulin-like receptors (KIRs) and their HLA ligands in Iranian patients with myasthenia gravis
Copyright © 2024. Published by Elsevier B.V..
BACKGROUND: Myasthenia gravis (MG) is a disabling disease with the underlying pathophysiology of auto-antibodies attacking the postsynaptic acetylcholine receptors of neuromuscular junctions causing muscle weakness. Natural killer (NK) cells are innate immune cells that play an important regulative role in immune responses. The human killer-cell immunoglobulin-like receptors (KIRs) family is one of the receptors on NK cells that can either activate or inhibit NK cells. This study aimed to assess the possible role of KIR and their human leukocyte antigen (HLA) ligand genes susceptibility to MG in Iranian patients.
METHOD: One hundred and sixty-three patients with MG diagnosis based on the presence of clinical symptoms and laboratory tests and 400 healthy volunteers were studied. We used the polymerase chain reaction (PCR) technique for genotyping 15 KIRs and 5 HLA genes.
RESULTS: The results demonstrated that there was no significant difference in the frequency of KIR genes and inhibitory KIR genotypes between controls and patients. In MG patients, HLA-C1Asn80 was significantly less frequent than in matched controls. The frequency of HLA genotype number 7 was significantly lower in MG cases, compared to the controls. Analysis of activating KIR genotypes showed that genotype number 10 was significantly less frequent in MG cases than in matched controls.
CONCLUSION: Our results suggest that the presence HLA-C1Asn80 might play a protective role against the pathogenesis of MG. The significantly decreased prevalence of one activating KIR genotype and one of the HLA genotypes in MG cases suggest that these genotypes can reduce the risk of MG development. To specifically reveal the impact of KIR and HLA in MG, more studies are required.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:238 |
|---|---|
| Enthalten in: |
Clinical neurology and neurosurgery - 238(2024) vom: 26. März, Seite 108171 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jalalvand, Mobina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Genetic association |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 29.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clineuro.2024.108171 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36912636X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36912636X | ||
| 003 | DE-627 | ||
| 005 | 20240331001033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clineuro.2024.108171 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM36912636X | ||
| 035 | |a (NLM)38422742 | ||
| 035 | |a (PII)S0303-8467(24)00058-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jalalvand, Mobina |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The investigation of killer-cell immunoglobulin-like receptors (KIRs) and their HLA ligands in Iranian patients with myasthenia gravis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: Myasthenia gravis (MG) is a disabling disease with the underlying pathophysiology of auto-antibodies attacking the postsynaptic acetylcholine receptors of neuromuscular junctions causing muscle weakness. Natural killer (NK) cells are innate immune cells that play an important regulative role in immune responses. The human killer-cell immunoglobulin-like receptors (KIRs) family is one of the receptors on NK cells that can either activate or inhibit NK cells. This study aimed to assess the possible role of KIR and their human leukocyte antigen (HLA) ligand genes susceptibility to MG in Iranian patients | ||
| 520 | |a METHOD: One hundred and sixty-three patients with MG diagnosis based on the presence of clinical symptoms and laboratory tests and 400 healthy volunteers were studied. We used the polymerase chain reaction (PCR) technique for genotyping 15 KIRs and 5 HLA genes | ||
| 520 | |a RESULTS: The results demonstrated that there was no significant difference in the frequency of KIR genes and inhibitory KIR genotypes between controls and patients. In MG patients, HLA-C1Asn80 was significantly less frequent than in matched controls. The frequency of HLA genotype number 7 was significantly lower in MG cases, compared to the controls. Analysis of activating KIR genotypes showed that genotype number 10 was significantly less frequent in MG cases than in matched controls | ||
| 520 | |a CONCLUSION: Our results suggest that the presence HLA-C1Asn80 might play a protective role against the pathogenesis of MG. The significantly decreased prevalence of one activating KIR genotype and one of the HLA genotypes in MG cases suggest that these genotypes can reduce the risk of MG development. To specifically reveal the impact of KIR and HLA in MG, more studies are required | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Genetic association | |
| 650 | 4 | |a Killer cell immunoglobulin-like receptor | |
| 650 | 4 | |a Myasthenia gravis | |
| 650 | 4 | |a Natural killer cell | |
| 650 | 7 | |a Immunoglobulins |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Receptors, KIR |2 NLM | |
| 650 | 7 | |a HLA Antigens |2 NLM | |
| 700 | 1 | |a Beigmohammadi, Fereshteh |e verfasserin |4 aut | |
| 700 | 1 | |a Soltani, Samaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Ehsan, Soroush |e verfasserin |4 aut | |
| 700 | 1 | |a Rajabkhah, Sahebeh |e verfasserin |4 aut | |
| 700 | 1 | |a Madreseh, Elham |e verfasserin |4 aut | |
| 700 | 1 | |a Akhtari, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Jamshidi, Ahmadreza |e verfasserin |4 aut | |
| 700 | 1 | |a Farhadi, Elham |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoudi, Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Nafissi, Shahriar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical neurology and neurosurgery |d 1993 |g 238(2024) vom: 26. März, Seite 108171 |w (DE-627)NLM000340820 |x 1872-6968 |7 nnns |
| 773 | 1 | 8 | |g volume:238 |g year:2024 |g day:26 |g month:03 |g pages:108171 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clineuro.2024.108171 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 238 |j 2024 |b 26 |c 03 |h 108171 | ||